VTU Technology GmbH. (2/10/15). "Press Release: Boehringer Ingelheim Renews Global Technology Collaboration Agreement with VTU Technology". Vienna & Grambach.

	Region	ALL
	Organisation	VTU Technology GmbH
	Today	Validogen GmbH
	Group	KonValue (Group)
	Organisation 2	Boehringer Ingelheim RCV GmbH & Co. KG
	Group	Boehringer Ingelheim (Group)
	Product	Pichia yeast expression system
	Product 2	recombinant protein production in yeast cells
	Index term	Boehringer–VTU: recombinant protein production, 201502– collab ww renewal of agreem for Pichia pastoris technology
	Person	Purkarthofer, Thomas (VTU Technology 201412 Head Business Development)

Boehringer Ingelheim, a research-based, global pharmaceutical company, and VTU Technology, a leading contract research and development company, announced today the renewal of their global Pichia pastoris technology collaboration agreement.

VTU Technology, currently offering a very broad and versatile technology platform available for Pichia pastoris protein production, will be responsible for carrying out the joint development program in VTU´s facilities in close collaboration between researchers from both companies. Boehringer Ingelheim has decided to prolong their ongoing technology agreement with VTU to further strengthen Pichia´s position as a highly attractive and competitive host for the production of biopharmaceuticals.

“The ongoing commitment of Boehringer Ingelheim in our technology collaboration underlines the skills and capabilities of our great team. We are very much looking forward to new exciting developments in this fruitful collaboration”, said Dr. Thomas Purkarthofer, Head of Business Development at VTU Technology.

“We are excited about the continuation of our successful collaboration with VTU Technology. Together we established Pichia pastoris as innovative platform for the manufacture of biopharmaceuticals,” said Georg Klima, Executive Director Process Science Austria at Boehringer Ingelheim. “With the renewal of our collaboration we will further expand our technological lead for Boehringer Ingelheim’s own development projects as well as for Boehringer Ingelheim BioXcellenceTM customers globally.”

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5 % of its net sales.

For more information, please visit www.boehringer-ingelheim.com
Twitter: www.twitter.com/boehringer

As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 20 biopharmaceutical products to market. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its new brand Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one brand at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.

More information: www.bioxcellence.com

About VTU Technology

VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression / production enabling highest productivities delivering up to 22 g/L of secreted protein within a few weeks development time. VTU´s yield-enhancing Pichia pastoris expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening & cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance.

Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science as well as power and fuel industry. More information: www.vtu-technology.com, www.vtu.com

Contact Boehringer Ingelheim:

Mag. Matthias Sturm
Communications Austria
Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer-Gasse 5 – 11
A-1121 Wien
Tel. +43-1-80105-2230
Email: matthias.sturm@boehringer-ingelheim.com

Contact VTU Technology:

Dr. Thomas Purkarthofer
Head of Business Development
Parkring 18
A-8074 Grambach
Tel: +43-316-4009-4017
Email: thomas.purkarthofer@vtu.com

Record changed: 2017-04-02